BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24318095)

  • 21. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?
    Kim KM; Sinn DH; Jung SH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Liver Int; 2016 Oct; 36(10):1490-7. PubMed ID: 26936471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging.
    Su TH; Liao SH; Hong CM; Liu CJ; Tseng TC; Liu CH; Yang HC; Chen PJ; Chen DS; Chen CL; Adhoute X; Bourlière M; Kao JH
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2179-2186. PubMed ID: 31062879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages.
    D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Marti P; Bilbao JI; Martinez-Cuesta A; Benito A; Alegre F; Mauleón E; Herrero JI; Quiroga J; Prieto J; Sangro B
    Ann Surg Oncol; 2011 Jul; 18(7):1964-71. PubMed ID: 21267791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy.
    Longo L; Rodrigues de Freitas LB; Santos D; Grivicich I; Álvares-da-Silva MR
    Am J Clin Oncol; 2019 May; 42(5):466-471. PubMed ID: 30913090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of clinical management and outcome in hepatocellular carcinoma nowadays compared with historical cohorts.
    Schellhaas B; Strobel D; Stumpf M; Ganslmayer M; Pfeifer L; Goertz RS; Neurath MF; Zopf S
    Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1422-1427. PubMed ID: 30052538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B?
    Wan L; Dong DH; Wu XN; Ding HF; Lu Q; Tian Y; Zhang XF; Li W
    Med Sci Monit; 2020 Oct; 26():e926797. PubMed ID: 33060558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
    Kwak HW; Park JW; Nam BH; Yu A; Woo SM; Kim TH; Kim SH; Koh YH; Kim HB; Park SJ; Lee WJ; Hong EK; Kim CM
    J Gastroenterol Hepatol; 2014 Apr; 29(4):820-9. PubMed ID: 24325272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study.
    Hong TP; Gow PJ; Fink M; Dev A; Roberts SK; Nicoll A; Lubel JS; Kronborg I; Arachchi N; Ryan M; Kemp WW; Knight V; Sundararajan V; Desmond P; Thompson AJ; Bell SJ
    Med J Aust; 2018 Oct; 209(8):348-354. PubMed ID: 30309301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma.
    Chen GX; Qi CY; Hu WJ; Wang XH; Hua YP; Kuang M; Peng BG; Li SQ
    BMC Cancer; 2020 May; 20(1):487. PubMed ID: 32471389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma.
    Wang JH; Kee KM; Lin CY; Hung CH; Chen CH; Lee CM; Lu SN
    J Gastroenterol Hepatol; 2015 Feb; 30(2):358-63. PubMed ID: 25088668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?
    Jianyong L; Lunan Y; Wentao W; Yong Z; Bo L; Tianfu W; Minqing X; Jiaying Y
    Medicine (Baltimore); 2014 Nov; 93(26):e180. PubMed ID: 25474433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
    Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
    Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma.
    Kim HC; Suk KT; Kim DJ; Yoon JH; Kim YS; Baik GH; Kim JB; Kim CH; Sung H; Choi JY; Han KH; Park SH
    World J Gastroenterol; 2014 Jan; 20(3):745-54. PubMed ID: 24574748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
    Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
    J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania.
    Guarino M; Tortora R; de Stefano G; Coppola C; Morisco F; Salomone Megna A; Izzo F; Nardone G; Piai G; Adinolfi LE; D'Adamo G; Gaeta GB; Messina V; Francica G; De Girolamo V; Coppola N; Persico M; Di Costanzo GG;
    J Gastroenterol Hepatol; 2018 May; 33(5):1123-1130. PubMed ID: 28994145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Improvement in 1-Year Survival Rate of Patients with Hepatocellular Carcinoma BCLC Stage A and B after the Implementation of Comprehensive Management.
    Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
    J Gastrointest Cancer; 2020 Sep; 51(3):829-835. PubMed ID: 31502104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in Pathology, Staging, and Treatment between HIV
    Torgersen J; Taddei TH; Park LS; Carbonari DM; Kallan MJ; Mitchell Richards K; Zhang X; Jhala D; Bräu N; Homer R; D'Addeo K; Mehta R; Skanderson M; Kidwai-Khan F; Justice AC; Lo Re V
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):71-78. PubMed ID: 31575557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee PC; Loong CC; Chiang JH; Huo TI; Lee SD
    Cancer; 2010 Jun; 116(12):3006-14. PubMed ID: 20564406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm.
    Richani M; Kolly P; Knoepfli M; Herrmann E; Zweifel M; von Tengg-Kobligk H; Candinas D; Dufour JF
    Ann Hepatol; 2016; 15(1):82-90. PubMed ID: 26626644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.